Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.

Aventis Narrows to 3 in $100 Mil. Lantus Review

NEW YORK—Aventis Pharmaceuticals cut to three shops on Friday in a global review for its Lantus diabetes drug, sources said. Billings are estimated at $100 million. The cut came after presentations last week by five agencies: Interpublic Group’s McCann-Erickson; Omnicom Group’s TBWA Worldwide; Havas’ Euro RSCG; Grey Global Group’s Healthy Grey and WPP Group’s Young & Rubicam, said sources. Each agency partnered with sister shops that handle media buying and other specialty disciplines.

AW+

WORK SMARTER - LEARN, GROW AND BE INSPIRED.

Subscribe today!

To Read the Full Story Become an Adweek+ Subscriber

View Subscription Options

Already a member? Sign in